Gut-directed hypnotherapy significantly augments clinical remission in quiescent ulcerative colitis

L. Keefer*, Tiffany Noel Taft, J. L. Kiebles, Zoran Martinovich, T. A. Barrett, O. S. Palsson

*Corresponding author for this work

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Background Psychotherapy is not routinely recommended for in ulcerative colitis (UC). Gut-directed hypnotherapy (HYP) has been linked to improved function in the gastrointestinal tract and may operate through immune-mediated pathways in chronic diseases. Aims To determine the feasibility and acceptability of HYP and estimate the impact of HYP on clinical remission status over a 1-year period in patients with an historical flare rate of 1.3 times per year. Methods A total of 54 patients were randomised at a single site to seven sessions of gut-directed HYP (n = 26) or attention control (CON; n = 29) and followed for 1 year. The primary outcome was the proportion of participants in each condition that had remained clinically asymptomatic (clinical remission) through 52 weeks post treatment. Results One-way analysis of variance comparing HYP and CON subjects on number of days to clinical relapse favoured the HYP condition [F = 4.8 (1, 48), P = 0.03] by 78 days. Chi-squared analysis comparing the groups on proportion maintaining remission at 1 year was also significant [χ2(1) = 3.9, P = 0.04], with 68% of HYP and 40% of CON patients maintaining remission for 1 year. There were no significant differences between groups over time in quality of life, medication adherence, perceived stress or psychological factors. Conclusion This is the first prospective study that has demonstrated a significant effect of a psychological intervention on prolonging clinical remission in patients with quiescent ulcerative colitis (Clinical Trial # NCT00798642).

Original languageEnglish (US)
Pages (from-to)761-771
Number of pages11
JournalAlimentary Pharmacology and Therapeutics
Volume38
Issue number7
DOIs
StatePublished - Oct 1 2013

Fingerprint

Hypnosis
Ulcerative Colitis
Psychology
Medication Adherence
Psychotherapy
Gastrointestinal Tract
Analysis of Variance
Chronic Disease
Quality of Life
Clinical Trials
Prospective Studies
Recurrence

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology
  • Pharmacology (medical)

Cite this

@article{5a816bbd28f04812a7ce47a0c934319e,
title = "Gut-directed hypnotherapy significantly augments clinical remission in quiescent ulcerative colitis",
abstract = "Background Psychotherapy is not routinely recommended for in ulcerative colitis (UC). Gut-directed hypnotherapy (HYP) has been linked to improved function in the gastrointestinal tract and may operate through immune-mediated pathways in chronic diseases. Aims To determine the feasibility and acceptability of HYP and estimate the impact of HYP on clinical remission status over a 1-year period in patients with an historical flare rate of 1.3 times per year. Methods A total of 54 patients were randomised at a single site to seven sessions of gut-directed HYP (n = 26) or attention control (CON; n = 29) and followed for 1 year. The primary outcome was the proportion of participants in each condition that had remained clinically asymptomatic (clinical remission) through 52 weeks post treatment. Results One-way analysis of variance comparing HYP and CON subjects on number of days to clinical relapse favoured the HYP condition [F = 4.8 (1, 48), P = 0.03] by 78 days. Chi-squared analysis comparing the groups on proportion maintaining remission at 1 year was also significant [χ2(1) = 3.9, P = 0.04], with 68{\%} of HYP and 40{\%} of CON patients maintaining remission for 1 year. There were no significant differences between groups over time in quality of life, medication adherence, perceived stress or psychological factors. Conclusion This is the first prospective study that has demonstrated a significant effect of a psychological intervention on prolonging clinical remission in patients with quiescent ulcerative colitis (Clinical Trial # NCT00798642).",
author = "L. Keefer and Taft, {Tiffany Noel} and Kiebles, {J. L.} and Zoran Martinovich and Barrett, {T. A.} and Palsson, {O. S.}",
year = "2013",
month = "10",
day = "1",
doi = "10.1111/apt.12449",
language = "English (US)",
volume = "38",
pages = "761--771",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "7",

}

Gut-directed hypnotherapy significantly augments clinical remission in quiescent ulcerative colitis. / Keefer, L.; Taft, Tiffany Noel; Kiebles, J. L.; Martinovich, Zoran; Barrett, T. A.; Palsson, O. S.

In: Alimentary Pharmacology and Therapeutics, Vol. 38, No. 7, 01.10.2013, p. 761-771.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Gut-directed hypnotherapy significantly augments clinical remission in quiescent ulcerative colitis

AU - Keefer, L.

AU - Taft, Tiffany Noel

AU - Kiebles, J. L.

AU - Martinovich, Zoran

AU - Barrett, T. A.

AU - Palsson, O. S.

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Background Psychotherapy is not routinely recommended for in ulcerative colitis (UC). Gut-directed hypnotherapy (HYP) has been linked to improved function in the gastrointestinal tract and may operate through immune-mediated pathways in chronic diseases. Aims To determine the feasibility and acceptability of HYP and estimate the impact of HYP on clinical remission status over a 1-year period in patients with an historical flare rate of 1.3 times per year. Methods A total of 54 patients were randomised at a single site to seven sessions of gut-directed HYP (n = 26) or attention control (CON; n = 29) and followed for 1 year. The primary outcome was the proportion of participants in each condition that had remained clinically asymptomatic (clinical remission) through 52 weeks post treatment. Results One-way analysis of variance comparing HYP and CON subjects on number of days to clinical relapse favoured the HYP condition [F = 4.8 (1, 48), P = 0.03] by 78 days. Chi-squared analysis comparing the groups on proportion maintaining remission at 1 year was also significant [χ2(1) = 3.9, P = 0.04], with 68% of HYP and 40% of CON patients maintaining remission for 1 year. There were no significant differences between groups over time in quality of life, medication adherence, perceived stress or psychological factors. Conclusion This is the first prospective study that has demonstrated a significant effect of a psychological intervention on prolonging clinical remission in patients with quiescent ulcerative colitis (Clinical Trial # NCT00798642).

AB - Background Psychotherapy is not routinely recommended for in ulcerative colitis (UC). Gut-directed hypnotherapy (HYP) has been linked to improved function in the gastrointestinal tract and may operate through immune-mediated pathways in chronic diseases. Aims To determine the feasibility and acceptability of HYP and estimate the impact of HYP on clinical remission status over a 1-year period in patients with an historical flare rate of 1.3 times per year. Methods A total of 54 patients were randomised at a single site to seven sessions of gut-directed HYP (n = 26) or attention control (CON; n = 29) and followed for 1 year. The primary outcome was the proportion of participants in each condition that had remained clinically asymptomatic (clinical remission) through 52 weeks post treatment. Results One-way analysis of variance comparing HYP and CON subjects on number of days to clinical relapse favoured the HYP condition [F = 4.8 (1, 48), P = 0.03] by 78 days. Chi-squared analysis comparing the groups on proportion maintaining remission at 1 year was also significant [χ2(1) = 3.9, P = 0.04], with 68% of HYP and 40% of CON patients maintaining remission for 1 year. There were no significant differences between groups over time in quality of life, medication adherence, perceived stress or psychological factors. Conclusion This is the first prospective study that has demonstrated a significant effect of a psychological intervention on prolonging clinical remission in patients with quiescent ulcerative colitis (Clinical Trial # NCT00798642).

UR - http://www.scopus.com/inward/record.url?scp=84883484059&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883484059&partnerID=8YFLogxK

U2 - 10.1111/apt.12449

DO - 10.1111/apt.12449

M3 - Article

C2 - 23957526

AN - SCOPUS:84883484059

VL - 38

SP - 761

EP - 771

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 7

ER -